Hormonal and Clinical Predictors for Post-egg Retrieval Pain in Women Undergoing Assisted Reproductive Technology Procedures by Vuilleumier, Pascal Henri et al.
  
 
Hormonal and clinical predictors for post-egg retrieval pain in women undergoing assisted 
reproductive technology procedures 
Authors 
Pascal H. Vuilleumier 
a
, Emily Dinges 
a
, Christopher Ciliberto 
a
, Clemens M. Ortner 
a
, Paul 
Zarutskie 
b
, Ruth Landau 
a
 
 
a 
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, 
USA
 
b 
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and 
Infertility, University of Washington, Seattle, WA, USA 
Corresponding author 
Ruth Landau, MD 
Professor of Anesthesiology 
Columbia University Medical Center 
Columbia University College of Physicians & Surgeons 
630 West 168th St PH-5  
New York, NY 10032 
Office: (212) 305-7412, Mobile (206) 605-4527 
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
The Clinical Journal of Pain Publish Ahead of Print
DOI:10.1097/AJP.0000000000000251
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
69
45
2 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
Email: rl262@cumc.columbia.edu 
The authors declare no conﬂict of interest. 
  
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
 Abstract  
Objectives 
The intensity of post-egg retrieval pain is underestimated, with few studies examining post-
procedural pain and predictors to identify women at risk for severe pain.  We evaluated the 
influence of pre-procedural hormonal levels, ovarian factors, as well as mechanical temporal 
summation (mTS) as predictors for post-egg retrieval pain in women undergoing in vitro 
fertilization (IVF). 
Methods 
Eighteen women scheduled for ultrasound-guided egg retrieval under standardized anesthesia 
and post-procedural analgesia were enrolled. Pre-procedural mTS, questionnaires, clinical 
data related to anesthesia and the procedure itself, post-procedural pain scores and pain 
medication for breakthrough pain were recorded. Statistical analysis included Pearson 
product moment correlations, Mann-Whitney U tests and multiple linear regressions.   
Results 
Average peak post-egg retrieval pain during the first 24 hours was 5.0 ± 1.6 on an NRS scale 
(0=no pain, 10=worst pain imaginable). Peak post-egg retrieval pain was correlated with 
basal antimullerian hormone (AMH) (r=0.549, p=0.018), pre-procedural peak estradiol 
(r=0.582, p=0.011), total number of follicles (r=0.517, p=0.028) and number of retrieved 
eggs (r=0.510, p=0.031). Ovarian hyperstimulation syndrome (OHSS) (n=4) was associated 
with higher basal AMH (p=0.004), higher peak pain scores (p=0.049), but not with peak 
estradiol (p=0.13). The mTS did not correlate with peak post-procedural pain (r=0.266, 
p=0.286), or peak estradiol level (r=0.090, p=0.899).  
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Discussion 
Peak post-egg retrieval pain intensity was higher than anticipated. Our results suggest that 
post-egg retrieval pain can be predicted by baseline AMH, high peak estradiol, and OHSS. 
Further studies to evaluate intra- and post-procedural pain in this population are needed, as 
well as clinical trials to assess post-procedural analgesia in women presenting with high 
hormonal levels. 
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Introduction 
In the Unites States, more than 150,000 assisted reproductive technology (ART) procedures 
were performed in 2011 [1] with numbers anticipated to further increase. Oocyte retrieval is 
only one of many steps and painful procedures that women will experience before becoming 
a parent. Women undergoing ART report escalating pelvic discomfort in the later stages of 
ovulation induction and most women use potent analgesics following oocyte retrieval 
procedures [2, 3]. Because post-procedural pain has not been extensively studied and 
management is challenging due to concerns that anti-inflammatory drugs may interfere with 
the fertility process, women are at risk for being either under or over-treated with prescribed 
opioids that may not necessarily be effective or even needed.  
Discomfort and pain after ART has been attributed to the mechanical process of ovarian 
enlargement similar to midcycle pelvic pain (Mittleschmerz) [4], the operative procedure 
itself, and the resulting post-operative accumulation of peritoneal fluid and blood [5]. The 
ovulation induction protocols utilized in ART are designed to induce supraphysiologic 
oocyte recruitment.  With continued ovulation induction, follicular recruitment results in 
significant bilateral ovarian enlargement from multiple follicles and supraphysiologic 
estradiol levels. In recent years, estradiol (E2) has been increasingly studied as a modulator 
of pain involved at the level of the dorsal horn and NMDA transmission [6-8]. However, the 
impact on pain modulation and pain perception of the supraphysiologic levels of estradiol 
and the overall altered endocrine state seen in ART, have not been investigated. 
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 Quantitative sensory tests (QST) evaluate the psychophysical response to experimental 
noxious stimuli, allowing quantification of clinically relevant pain thresholds and tolerance 
[9]. Simple bedside testing of mechanical temporal summation (mTS) with a Von Frei 
filament has been shown to predict acute post-operative pain [12, 13] and chronic pain 
disorders [14-16] in clinical studies. Only a handful of studies have utilized QST to evaluate 
the influence of hormonal stimulation for ART on pain perception [17-19], and none has 
evaluated pre-procedural pain testing or hormonal assays with post-procedural pain. 
Increased sensitivity to thermal cutaneous pain was found in 31 women undergoing ART but 
only at supraphysiologic E2 levels [17]. No association between hormone levels at different 
time-points during hormonal stimulation and a variety of QST was found in another study in 
16 women undergoing ART [18], and only reductions in cold water tolerance, but not in 
pressure pain were found in another study in 40 women [19].  
We decided to characterize post-egg retrieval pain and analgesic consumption, as well as 
identify clinical predictors for severe post-procedural pain, defined as a pain score of more 
than 7 on a scale from 0-10. We therefore designed a prospective, observational study 
exploring mTS, pain scores and analgesic intake, questionnaires to assess anxiety, fear and 
catastrophization traits (Spielberger’s State-Trait Anxiety Inventory, Pain Catastrophizing 
Scale, Fear of Pain, Short-form McGill Pain Questionnaire (SF-MPQ) and hormonal levels to 
study the association between these parameters and post-egg retrieval pain. 
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Materials and Methods 
Ethical consent 
The study was approved by the University of Washington ethics committee (No. 35811-A), 
registered in the Clinical Trials Protocol Registration System (NCT00867945), and 
performed in accordance with the Declaration of Helsinki. Written informed consent was 
obtained from all subjects. 
Subjects 
Nulliparous women scheduled for egg retrieval after hormonal stimulation were approached 
the day before the egg retrieval procedure. Women were considered eligible if they were 
healthy, aged 18-45 years, with no prior history of anxiety, no depression or chronic pain and 
no chronic opioid consumption. Intake of non-steroidal anti-inflammatory drugs (NSAIDs) 
or acetaminophen 48 hours prior to the egg retrieval was not allowed, as per clinical protocol 
at the Division of ART at the University of Washington. 
Hormonal assays 
Prior to enrollment in the IVF cycle, antimullerian hormone (AMH), thyroid panel, prolactin, 
and a baseline (day 2-4 of menstrual cycle) E2 and FSH were measured in all women.  E2 
levels were drawn at the start of the IVF cycle, on monitored stimulation days, and on the 
morning after hCG administration (peak E2) (Figure 1). 
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 Ultrasound assessments 
Serial transvaginal ultrasounds were performed per clinical protocol to determine follicular 
growth and timing for hCG administration, as well as the total follicle number (follicles 
greater than 8 mm) and lead follicles (greater than 14 mm). Follicle growth was assessed by 
serial transvaginal ultrasounds, starting from stimulation day 5 and thereafter as often as 
necessary in order to ensure that the antagonist and the hCG administration met protocol.  On 
the day of hCG administration ultrasound assessment included recording total number and 
mean diameters for all follicles above 8mm size. Transvaginal ultrasound oocyte retrieval 
was performed 36 hours after hCG administration. 
Ovarian stimulation  
In vitro fertilization (IVF) ovulation induction protocol (Figure 1) was initiated with oral 
contraceptive pretreatment. After a baseline transvaginal ultrasound, E2 and progesterone 
levels to confirm ovarian suppression (day 1 of a 10 day stimulation cycle), ovarian 
stimulation was initiated. A gonadotropin/antagonist/ovulation induction protocol was 
followed and employed a combination of recombinant FSH (Gonal-F™, Merck Serono) and 
menotropin (Menopur™, Ferring). With follicular recruitment achieving lead follicles of 12-
13mm mean diameter, a GnRH antagonist (Cetrotide™, Merck Serono) was begun at a daily 
dose of 0.25mg. With lead follicle cohort of at least 17mm mean diameter and a total serum 
E2 reflective of 200-250 pg/ml per follicles, final oocyte maturation was induced by 
administering 10,000 IU of hCG (Noverel™, Ferring).  
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 Egg retrieval procedure   
Using a standardized technique under ultrasound guidance and with general anesthesia, the 
aspiration needle (OVA-Stiff, 16 GA/35 cm, Cook Medical, Brisbane, QLD, Australia) was 
inserted through the vaginal wall and into the ovary. In a serial fashion, follicular aspiration 
was performed of all follicles greater than 13mm size. To minimize the number of 
transvaginal/ovarian wall punctures, the needle was kept in the aspirated/collapsed follicle 
and advanced to the next adjacent follicle. Once all follicles in a given ovary were aspirated 
and oocyte identification complete, the needle was removed. The pelvis and ovary were 
observed with transvaginal Doppler, and if necessary hemostasis was achieved with 
approximated manual abdominal pressure with vaginal probe pressure. With adequate 
observation of hemostasis, transvaginal egg retrieval was resumed and follicular aspiration of 
the remaining ovary was completed. Upon completion of the transvaginal egg retrieval and a 
transvaginal Doppler ultrasound confirming hemostasis, anesthesia was discontinued and 
patients transferred to the post-anesthesia care unit (PACU).  
The luteal phase was supplemented daily with vaginal progesterone (Crinone 8%, Watson) 
and oral E2 6mg (2mg three times a day), beginning the morning after oocyte recovery.  
Anesthesia and post-egg retrieval analgesia 
Anesthesia was provided by a dedicated team of obstetric anesthesiologists following a 
standardized protocol and in keeping with clinical standards requested by the Division of 
ART at the University of Washington. This protocol included intravenous (IV) midazolam 
2mg, fentanyl 50-200mcg, propofol (1-2mg/kg) titrated to loss of consciousness and 
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maintained with a continuous infusion (50-150mcg/kg/min), ondansetron 4mg and 
dexamethasone 4mg. At the end of the procedure and after regaining consciousness, women 
were monitored in the PACU for two hours, and offered oral hydrocodone 5mg - 
acetaminophen 500mg. Breakthrough pain was treated with additional IV fentanyl at the 
discretion of the anesthesiologist. Women were instructed to manage post-egg retrieval pain 
with hydrocodone 5mg and acetaminophen 500mg tablets per need.   
Study procedures  
Written consent was obtained the morning of the procedure. Two research coordinators not 
involved with clinical care collected all the pre-procedural questionnaires, performed mTS 
and the 24 hours phone pain follow-up.  The full study flow is presented in Figure 2.  
 Questionnaires: 
On the day of egg-retrieval and before any procedure-related intervention was started, 
women completed written questionnaires recording demographic data, general health 
information, as well as validated questionnaires to assess anxiety, fear and catastrophization 
traits (Spielberger’s State-Trait Anxiety Inventory, Pain Catastrophizing Scale, Fear of Pain, 
Short-form McGill Pain Questionnaire (SF-MPQ) [21, 22].   
 Mechanical temporal summation (mTS):  
In sum, mTS was evoked with a 180 g (#6.45) von Frey filament (North Coast Medical, San 
Jose, California) applied to the volar aspect of the dominant forearm. Women were asked to 
report their pain intensity on a 101 - point verbal numerical response scale (NRS; 0 = no 
pain, 100 = worst pain imaginable) from a single stimulus pinprick. Subsequently, ten 
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repetitive stimuli with an inter-stimulus interval of 1 second were applied within an area of 1 
cm in diameter using the same filament, and women were asked to rate the pain intensity of 
the last stimulus. The mTS score calculated as the difference between the last and first pain 
scores, with a positive score indicating increased excitatory central pain facilitation [12], as 
previously described [13]. 
 Pain outcomes:  
Women were contacted by phone the day after the procedure and answered questions on a 
scripted interview assessing their peak pain (numeral pain score 0-10; 0=no pain, 10=worst 
pain imaginable), analgesic consumption (tablets taken), and pain after taking pain 
medication (numeral pain score 0-10; 0=no pain, 10=worst pain imaginable). 
 
Statistical Analysis   
Descriptive categorical and numerical variables are presented as percentages or means ± 
standard deviation. P values < 0.05 were considered significant. All available variables 
fulfilled normal distribution criteria. Mann-Whitney U tests were performed, investigating 
the impact of ovarian hyperstimulation syndrome (OHSS) on peak E2, basal AMH levels and 
peak post-procedural pain.  Data were analyzed using SPSS 19 (SPSS Inc; Chicago, IL).
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Results 
During the study period, 20 women were enrolled into the study, with 18 completing all the 
measures and follow-up, as described in the study flowchart (Figure 1). The overview of all 
demographic parameters are presented in Table 1, pain measures and the Pearson product-
moment correlation coefficients are presented in Table 2.  
Women received on average IV fentanyl 97.2mcg ± 29.5 during the procedure and 
immediately after in the PACU. For post-procedural analgesia, women took on average 
16.1mg ± 13.2 oral hydrocodone and 1609mg ± 1325 oral acetaminophen in the first 24 
hours.  
All women experienced moderate to severe post-procedural pain (NRS peak pain score ≥ 
3/10). The average peak pain score in the first 24 hours after the procedure was 5.0 ± 1.6. 
The average pain score after taking pain medication was 2.7 ± 1.6, which was significantly 
lower than the peak post-procedural pain score (p<0.001) (Figure 3). Pain was described as 
sharp (n=6), crampy (n=14) and burning (n=1). A majority of patients experienced more pain 
than they expected (n=11).  
A Pearson product-moment correlation coefficient was computed to assess the strength of the 
linear association between peak post-procedural pain, demographic data, mTS, hormonal and 
procedural factors (number of retrieved eggs, surgical time, total follicles and lead follicles). 
Two separate standard multiple regressions were performed to keep a minimal number of 
variables in this small dataset and to avoid multicollinearity [23, 24]. A standard multiple 
regression analysis was conducted to assess potential correlations between age, BMI and 
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mTS and peak post-procedural pain. The regression equation for predicting maximal post-
procedural pain was:  
Peak post-procedural pain = (0.055*mTS) + (0.031 * BMI) - (0.116 * age) + 8.502. 
Procedure-related factors possibly explaining the maximal pain were evaluated separately for 
the above stated reasons. A standard multiple regression analysis was conducted exploring 
the correlation of peak post-procedural pain with the number of retrieved eggs, surgical time, 
total follicles and lead follicles.  The regression equation for predicting peak post-procedural 
pain was:  
Peak post-procedural pain= (0.179 * retrieved eggs) + (0.086 * total follicles) – (0.270* 
lead follicles) + (0.002* surgical time) + 3.711 
Peak post-procedural pain was significantly associated with 4 factors: basal AMH level 
(r=0.549, p=0.018), peak E2 level (r=0.582, p= 0.011), the total number of follicles (r=0.591, 
p=0.010) and the number of retrieved eggs (r=0.510, p=0.031) (Figure 4).  
The linear combination of procedural factors (surgical time, number of retrieved eggs, total 
follicles and lead follicles) was not significantly associated with post-procedural analgesic 
response, defined as the difference in pain score (NRS) between the peak post-procedural 
pain score and average pain score (NRS) after taking pain medication (F=0.418, p=0.793, 
R=0.338). 
Pre-procedural mTS score was 2.47 ± 4.7 (on a scale from 0-100; 0=no pain and 100= worst 
pain imaginable) and was neither associated with peak E2 levels (r=0.090, p=0.724), nor 
peak post-procedural pain (r=0.266, p=0.286). Peak E2 level was significantly associated 
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with basal AMH level (r=0.718, p=0.001), the total number of follicles (r=0.719, p=0.001), 
the number of lead follicles (r=0.638, p=0.014), and the number of retrieved eggs (r=0.831, 
p<0.001), 
The number of retrieved eggs was correlated with basal AMH level (r=0.701, p=0.001), the 
total number of follicles (r=0.752, p<0.001), and lead follicles (r=0.752, p<0.001). The total 
number of follicles was significantly correlated with basal AMH level (r=0.591, p=0.010) 
and lead follicles (r=0.688, p=0.002). 
The linear combination of demographic factors (age, BMI) and mTS was not significantly 
correlated with peak post-procedural pain, F (4,13)=1.329, R=0.471, R
2
=0.222. The multiple 
correlation coefficient was 0.471, indicating that approximately 22% of the variance of peak 
post-procedural pain can be accounted for by the linear combination of the predictors.  
The linear combination of procedural factors (surgical time, number of retrieved eggs, total 
follicles and lead follicles) was significantly correlated with peak post-procedural pain, F 
(4,13)=4.756, p=0.014. The multiple correlation coefficient was 0.771, indicating that 
approximately 60% of the variance of peak post-procedural pain can be accounted for by the 
linear combination of predictors, with the number of eggs (p=0.032) and the number of lead 
follicles (p=0.009) being statistically significant.  
There were 4 cases diagnosed with OHSS, using a cut-off of AMH level above 3.5 ng/ml 
[25]. Mann-Whitney U tests were performed, to evaluate the impact of ovarian 
hyperstimulation syndrome (OHSS) on peak E2, basal AMH levels and peak post-procedural 
pain. Women with OHSS had significantly higher levels of AMH (6.42ng/ml ±2,3) than 
women without OHSS (1.72ng/ml ±1.1; z=-2.91; p=0.004; mean rank with OHSS=14.5, 
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without OHSS=6.5). Peak post-procedural pain scores were higher in women with OHSS 
(z=-1.96; p=0.049; mean rank with OHSS=12.5, without OHSS=7.17). Peak E2 did not 
correlate with OHSS (z=-1.57, p=0.13; mean rank with OHSS=11.75, without OHSS=7.42). 
Discussion  
The main findings in this study are that women undergoing ultrasound-guided egg retrievals 
report moderate to severe peak-procedural pain that is described by most as sharp and 
exceeding their expectations. In addition, basal AMH levels and peak E2 levels were found 
to correlate with peak post-procedural pain, and may be used as predictors for severe pain in 
women with high pre-procedural hormonal levels. Basal AMH levels have been associated 
with the total number of follicles on the day of procedure, peak E2 levels and number of 
retrieved eggs [26], and are used as a predictor for follicular recruitment and influence 
medication protocols for adjusting gonadotropin stimulation [27, 28], but we provide here 
novel information suggesting it is also associated with the intensity of post-procedural pain. 
This association of basal AMH level and peak post-egg retrieval pain was not expected. 
Basal AMH levels AMH levels above 3.5 ng/ml have been associated with ovarian 
hyperstimulation [25]; and in our cohort, 4 women met criteria for OHSS.  
If ovarian distention is the main contributor to post-procedural pain, it would be expected 
that both the total number of recruited follicles as well as the number of lead follicles are 
associated with post-procedural pain. In our study, only the total number of recruited follicles 
and the number of retrieved eggs, but not the number of lead follicles, correlated in a 
multiple regression analysis predicting peak post-procedural pain. Our data suggests that the 
altered endocrine state seen in women undergoing fertility treatment contributes to post 
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sonographic egg recovery pain modulation: in particular the hormonal contribution related to 
the supraphysiologic levels of estradiol seen in ART in contrast to mechanical, anatomical or 
procedure-related factors, are causation for the post procedural pain. The exact implications 
of this finding remains to be established, and may be limited to our small sample. 
The intensity of pain reported by our cohort of women is substantially higher than that 
reported in a recent systematic review [5]. Explanations for this finding may be related to 
several factors, including the fact that women in our study did not receive regional anesthesia 
or local anesthetics, were not allowed to take NSAIDs before or after the procedure, and 
were given acetaminophen and hydrocodone-based tablets, which may not be as effective for 
crampy pain as other analgesic/anesthetic modalities. In addition, with 4 cases of OHSS 
(22% of our cohort), higher pain scores can be anticipated as we and others [19] found that 
supraphysiological levels of E2 are associated with higher sensitivity to pain.   
In a recent study evaluating symptoms such as abdominal pain and cramping, bloating, 
headaches, nausea, increased thirst, sweating, hunger, anxiety, irritability, vaginal discomfort 
and fatigue in 51 women undergoing IVF and 12 healthy controls, peak E2 levels were 
temporally associated with peak physical symptoms in the IVF group, supporting the 
hypothesis that increasing E2 levels influence symptom severity [3].  
We evaluated pre-operatively mTS, as this simple test has been previously shown to be 
associated with acute post-operative pain [12], and we hypothesized that in the context of 
high estrogen impregnation, increased ascending noxious input may result in abnormal wind-
up of pain. We did not find any correlation between mTS values and any of the outcomes. 
The lack of association with any of the measures outcomes and specifically with peak-
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procedural pain is most likely due to the fact that women in our cohort were all healthy, with 
no history of chronic pain, and were found to all have extremely low scores of mTS, 
therefore this test could not serve as a predictor in this setting. Alternatively, mTS may not be 
the most specific QST to predict pain that is essentially crampy by nature. Based on our 
findings, we can only conclude that mTS scores in otherwise healthy women do not seem to 
increase with the endocrine state induced by IVF. 
 
We are aware of several limitations in our study design, which require cautious interpretation 
of our findings. First, we acknowledge our small sample size, which was in part due to our 
desire to ensure the most standardized hormonal stimulation protocol and procedure 
technique, so we only enrolled cases performed by one specific ART provider. Second, 
women did not receive NSAIDs (as per protocol established by the ART provider), which 
resulted in relatively high pain scores in all women. Last, we did not examine the effect of 
elevated AMH levels and peak E2 on pain perception after different procedures or in a 
context that is not related with egg retrievals, therefore more studies will be needed to 
establish the correlation and potential mechanisms by which these two hormones may be 
negatively influencing pain perception in women. 
In sum, to the best of our knowledge, this is the first study evaluating pre-procedural 
hormonal levels, mechanical temporal summation, and procedural factors in the context of 
post egg-retrieval pain and analgesic consumption. Although the sample size is small and 
results have to be interpreted with caution, our findings are consistent and provide robust 
evidence for a correlation between basal AMH levels, peak E2 levels and the intensity of post 
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egg-retrieval pain. These findings linking hormonal levels to pain merit further investigation 
to improve post-procedural management.  
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Figure legends 
Figure 1. Study Flowchart 
Figure 2. Study protocol 
The entire IVF ovulation induction protocol is represented, with 10-21 
days of pretreatment cycle, 10 days of stimulation cycle, 2 days of 
maturation cycle, the procedure and following 24 hours. 
The study protocol included analysis of baseline E2, FSH, AMH levels, 
peak E2 levels, questionnaires, mTS, procedure related parameters, as well 
as by pain scores during the first 24 hours (all study measures are 
represented in bold red). 
E2 = estradiol 
FSH = Follicle Stimulating hormone 
AMH = Antimullerian hormone 
IVF = In Vitro Fertilization 
GnRH = gonadotropin-releasing hormone 
hCG = human chorionic gonadotropin 
mTS = mechanical temporal summation 
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Figure 3. Pain outcomes 
Peak pain post-egg retrieval was the worst pain during the first 24 hour 
after the procedure (presented as 18 individual scores, with a numerical 
rating scale from 0-10; 0=no pain, 10=worst pain imaginable). 
Pain after taking pain medication was the pain intensity women reported 
after taking pain medication (presented as 18 individual scores, with a 
numerical rating scale from 0-10; 0=no pain, 10=worst pain imaginable). 
Figure 4. Correlations between peak E2, baseline AMH, total number 
of follicles and number of retrieved eggs with peak post-procedural 
pain 
Correlations performed using Pearson correlation coefficient  
Figure 4A. Peak estradiol level correlated with peak pain post-egg 
retrieval (representing the worst pain during the first 24 hour after the 
procedure) 
Figure 4B. Baseline AMH level correlated with peak pain post-egg 
retrieval (representing the worst pain during the first 24 hour after the 
procedure) 
Figure 4C. Number of total follicles correlated with peak pain post-egg 
retrieval (representing the worst pain during the first 24 hour after the 
procedure) 
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Figure 4D. Number of retrieved eggs correlated with peak pain post-egg 
retrieval (representing the worst pain during the first 24 hour after the 
procedure) 
AMH = Antimullerian hormone 
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Excluded(n=39) 
-Declined to participate (n=34) 
-Medical reason (n=3) 
-Other (n=2) 
Received intervention  
& allocated to study (n=20)  
Lost to follow-up (n=2) 
Discontinued intervention (n=0) 
Assessed for eligibility (n=59) 
Analyzed (n=18) 
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                Table 1. Demographic variables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean ± standard deviation (SD). 
Peak pain = peak post-procedural pain (NRS scale from 0-10) 
Peak E2 = maximal plasmatic level measured after hormonal stimulation 
AMH = Antimullerian hormone,  
E2 =  plasmatic estradiol between days 2 -5  
FSH =  Follicle-stimulating hormone between days 2-5 
mTS = mechanical temporal summation 
Hydrocodone = analgesic intake of oral hydrocodone in the first 24h 
Paracetamol = analgesic intake of oral paracetamol in the first 24h 
Age (years) 36.1 (±5.6) 
Weight (kgs) 68.1 (±18.8) 
BMI (kgs/m
2
) 24.8 (±5.9) 
Peak E2 (pg/ml) 2720 (±1183) 
mTS score (0-10) 2.47 (±4.1) 
AMH (ng/ml) 2.9 (±2.6) 
E2 @ day 3 (pg/ml) 49.6 (±27.4) 
FSH @ day 3 (mIU/ml) 7.6 (±4.2) 
Procedure duration (min) 22.78 (±9.9) 
Fentanyl dose (mcg) 97.2 (±29.57) 
Retrieved eggs (N) 13.7 (±6.6) 
Total follicles (N) 18.3 (±10.1) 
Lead follicles (N) 10.3 (±5.1) 
Peak pain (NRS 0-10) 5.0 (±1.6) 
Hydrocodone (mg) 16.1 (±13.2) 
Paracetamol (mg) 1609 (±1325) 
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Table 2. Pearson correlation matrix 
 
Variable Age Weight BMI 
Procedure 
duration 
Fentanyl  Peak pain Peak E2 
Retrieved 
eggs 
Total 
follicles 
Lead 
follicles 
AMH E2 @day 3 FSH @day 3 mTS Hydrocodone 
Weight 
r=0.241, 
p=0.335 
x              
BMI 
r=0.310, 
p=0.210 
r=0.957, 
p<0.001* 
x             
Procedure duration 
r=-0.425, 
p=0.079 
R=-0.398, 
p=0.101 
r=-0.452, 
p=0.059 
x            
Fentanyl  
r=-0.002, 
p=0.994 
R=0.257, 
p=0.303 
r=0.295, 
p=0.235 
r=-0.380, 
p=0.120 
x           
Peak pain 
r=-0.427, 
p=0.077 
r=0.072, 
p=0.775 
r=0.006, 
p=0.982 
r=0.285, 
p=0.251 
r=0.247, 
p=0.322 
x          
Peak E2 
r=-0.359, 
p=0.144 
r=-0.106, 
p=0.667 
r=-0.134, 
p=0.059 
r=0.274, 
p=0.272 
r=0.171, 
p=0.498 
r=0.582, 
p=0.011* 
x         
Retrieved eggs 
r=-0.465, 
p=0.052 
r=-0.098, 
p=0.699 
r=0.152, 
p=0.548 
r=0.417, 
p=0.085 
r=-0.138, 
p=0.584 
r=0.510, 
p=0.031* 
r=0.831, 
p=<0.001* 
x        
Total follicles 
r=-0.523, 
p=0.026* 
r=-0.291, 
p=0.241 
r=-0.443, 
p=0.065 
r=0.591, p=0. 
010* 
r=-0.263, 
p=0.292 
r=0.517, 
p=0.028* 
r=0.719, 
p=0.001* 
r=0.752, 
p=<0.001* 
x       
Lead follicles 
r=-0.478, 
p=0.045* 
r=-0.279, 
p=0.262 
r=-0.338, 
p=0.170 
r=0.415, 
p=0.087 
r=-0.198, 
p=0.431 
r=0.079, 
p=0.756 
r=0.638, 
p=0.014* 
r=0.752, 
p=<0.001* 
r=0.688, 
p=0.002* 
x      
AMH 
r=-0.421, 
p=0.082 
r=-0.166, 
p=0.511 
r=-0.162, 
p=0.520 
r=0.396, 
p=0.104 
r=-0.168, 
p=0.506 
r=0.549, 
p=0.018* 
r=0.718, 
p=0.001* 
r=0.701, 
p=0.001* 
r=0.591, 
p=0.010* 
r=0.323, 
p=0.191 
x     
E2 @day 3 
r=0.150, 
p=0.553 
r=-0.131, 
p=0.604 
r=-0.195, 
p=0.437 
r=0.073, 
p=0.775 
r=0.057, 
p=0.823 
r=0.165, 
p=0.512 
r=0.442, 
p=0.066 
r=0.194, p=0.441 
r=0.371, 
p=0.129 
r=0.332, 
p=0.178 
r=0.256, 
p=0.306 
x    
FSH @day 3 
r=0.450, 
p=0.061 
r=-0.354, 
p=0.150 
r=-0.234, 
p=0.350 
r=-0.252, 
p=0.313 
r=0.050, 
p=0.844 
r=-0.315, p=0. 
203 
r=-0.152, 
p=0.546 
r=-0.161, 
p=0.524 
r=-0.355, 
p=0.149 
r=-0.110, 
p=0.663 
r=-0.199, 
p=0.428 
r=0.139, 
p=0.581 
x   
mTS 
r=-0.244, 
p=0.330 
r=0.220, 
p=0.381 
r=0.171, 
p=0.498 
r=0.048, 
p=0.849 
r=0.078, 
p=0.759 
r=0.266, 
p=0.286 
r=0.090, 
p=0.724 
r=0.032, p=0.899 
r=-0.060, 
p=0.812 
r=0.016, 
p=0.951 
r=-272, 
p=0.275 
r=-0.233, 
p=0.352 
r=-0.069, 
p=0.786 
x  
Hydrocodone 
r=-0.333, 
p=0.227 
r=-0.162, 
p=0.520 
r=-0.202, 
p=0.421 
r=0.291, 
p=0.242 
r=-0.079, 
p=0.755 
r=0.251, 
p=0.315 
r=0.084, 
p=0.738 
r=0.288, p=0.246 
r=0.131, 
p=0.605 
r=-0.039, 
p=0.876 
r=0.548, 
p=0.018* 
r=-0.045, 
p=0.859 
r=-0.186, 
p=0.474 
r=-0.288, 
p=0.246 
x 
Paracetamol 
r=-0.287, 
p=0.249 
r=-0.191, 
p=0.448 
r=-0.229, 
p=0.360 
r=0.307, 
p=0.216 
r=-0.077, 
p=0.760 
r=0.202, 
p=0.421 
r=0.075, 
p=0.767 
r=0.266, p=0.287 
r=0.116, 
p=0.647 
r=-0.044, 
p=0.862 
r=0.547, 
p=0.018* 
r=-0.042, 
p=0.866 
r=-0.207, 
p=0.425 
r=-0.326, 
p=0.187 
r=0.984,  
p<0.001* 
 
R = Pearson correlation coefficient 
* = p<0.05 (2-tailed) 
Peak pain = peak post-procedural pain on a NRS scale (0-10) 
Peak E2 = maximal plasmatic level measured after hormonal stimulation (pg/ml) 
AMH = Antimullerian hormone (ng/ml) 
E2 = peak plasmatic estradiol between days 2 -5 (pg/ml) 
FSH =  peak follicle-stimulating hormone between days 2-5 (mlU/ml) 
mTS = mechanical temporal summation score  (0-100) 
Hydrocodone = analgesic intake of hydrocodone in the first 24h (mg)  
Paracetamol = analgesic intake of paracetamol in the first 24h (mg) 
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